

Date: July 23, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Submission of Media Release pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Un-audited Standalone and Consolidated financial results of the Company for the quarter ended June 30, 2025 duly approved by the Board of Directors of the Company in their meeting held on July 23, 2025.

You are requested to take the same on your record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra

Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

SENORES PHARMACEUTICALS LIMITED

Strong Financial & Operational Performance for Q1FY26

Ahmedabad, Gujarat, 23rd July 2025 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its un-audited Financial Result for the first Quarter of FY26 ended 30th June 2025.

Q1 FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS

Total Income*

Rs.138 Crs

 **72%**

Y-o-Y for Q1 FY26

EBIDTA

Rs. 34 Crs

 **60%**

Y-o-Y for Q1 FY26


Profit after Tax (PAT)

Rs. 21 Crs


 **95%**

Y-o-Y for Q1 FY26


Total Income* (Rs.Crs)




EBITDA (Rs. Crs)




PAT (Rs.Crs)




Gross Margin (%)



EBITDA Margin (%)




PAT Margin (%)




* Total Income includes Revenue from Operations & Other Operating Income

Q1 FY26 OPERATIONAL & FINANCIAL HIGHLIGHTS


Revenue Mix (%)




Regulated Markets



Emerging Markets



Others



- For Q1FY26, **Regulated Markets** Revenue stood at Rs 90 crs, **growing by 69% Y-o-Y**. EBIDTA Margin for Regulated Markets business stood at 35.5% in Q1 FY26.
- For Q1 FY26, **Emerging Markets** Revenue stood at Rs. 29 crs, **growing by 32% Y-o-Y**. EBIDTA Margin for Emerging Markets business stood at 6% in Q1 FY26.
- In the Regulated Markets the company currently has:
 - 24 Own commercial products
 - 70 Approved ANDA products
 - 57 Pipeline products with 37 CGT opportunity products
 - 27 CDMO/CMO commercial products
 - 53 CDMO/CMO pipeline products
- For the Emerging Markets the company currently has:
 - 308 Registered products
 - 719 products under Registration
 - Presence across more than 40 countries

Commenting on the results, **Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“Continuing the momentum from last year, we have started FY26 well, with healthy performance across segments during the quarter.

We launched 2 own ANDA products in the Regulated Markets during the quarter. We also received the ANDA approval for 4 products during the quarter. We have a strong pipeline in place which we will launch over the next couple of years. Our moat lies in our ability to serve the government channel in addition to the retail channel in the US. This gives us considerable competitive advantage in the US market. A large part of our product pipeline has potential to cater to the government contracts. Our capability to manufacture and supply controlled substances in US is another differentiator for us.

Our CDMO / CMO segment is also scaling up as planned. We are adding new contracts and increasing the share of pocket from existing customers. The contracts in hand give us good visibility for the year ahead. With respect to the US tariff situation, we believe we are largely insulated with our entire formulation manufacturing happening locally in US.

In the Emerging Markets, our changing product portfolio and go-to-market strategies are resulting in improved profitability.

Our Branded Generics segment is witnessing significant uptick in momentum. On the back of increasing field force, our monthly revenue run rate has more than doubled versus last year. We expect to be a pan-India player by the end of FY26.

We are also pleased to report positive Operating Cash Flow of Rs 11 crores for Q1FY26. We expect to sustain and build on the cash flow trajectory going forward.

Our business is undergoing a structural advancement which will provide better market visibility and support the growth momentum for us over the medium term to longer term. We will continue to drive the business on three key pillars – (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; and (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 24 ANDA and 27 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 308 registered products and 719 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899